[1] Griffith HR, Johnson GE. The use of curare in general anesthesia[J]. Anesthesiology, 1942, 3(4): 418–420.
[2] Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action[J]. Anesthesiology, 2003, 98(5): 1042–1048.
[3] Kirmeier E, Eriksson LI, Lewald H, et al. Post-anaesthesia pulmonary complications after use of muscle relaxants (POPULAR): a multicentre, prospective observational study[J]. Lancet Respir Med, 2019, 7(2): 129–140.
[4] Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis[J]. Br J Anaesth, 2007, 98(3): 302–316.
[5] Kim KS, Lew SH, Cho HY, et al. Residual paralysis induced by either vecuronium or rocuronium after reversal with pyridostigmine[J]. Anesth Analg, 2002, 95(6): 1656–1660.
[6] Cammu G, De Witte J, De Veylder J, et al. Postoperative residual paralysis in outpatients versus inpatients[J]. Anesth Analg, 2006, 102(2): 426–429.
[7] Fortier LP, McKeen D, Turner K, et al. The RECITE study: a Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade[J]. Anesth Analg, 2015, 121(2): 366–372.
[8] Aytac I, Postaci A, Aytac B, et al. Survey of postoperative residual curarization, acute respiratory events and approach of anesthesiologists[J]. Braz J Anesthesiol, 2016, 66(1): 55–62.
[9] Butterly A, Bittner EA, George E, at al. Postoperative residual curarization from intermediate-acting neuromuscular blocking agents delays recovery room discharge[J]. Br J Anaesth, 2010, 105(3): 304–309.
[10] Kopman AF, Zank LM, Ng J, et al. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory?[J]. Anesth Analg, 2004, 98(1): 102–106.
[11] Donati F. Residual paralysis: a real problem or did we invent a new disease?[J]. Can J Anaesth, 2013, 60(7): 714–729.
[12] Kaufhold N, Schaller SJ, Stäuble CG, et al. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)[J]. Br J Anaesth, 2016, 116(2): 233–240.
[13] Viby-Mogensen J, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to train-of-four nerve stimulation[J]. Anesthesiology, 1985, 63(4): 440–443.
[14] Engbaek J, Ostergaard D, Viby-Mogensen J. Double burst stimulation (DBS): a new pattern of nerve stimulation to identify residual neuromuscular block[J]. Br J Anaesth, 1989, 62(3): 274–278.
[15] Brull SJ, Kopman AF. Current status of neuromuscular reversal and monitoring: challenges and opportunities[J]. Anesthesiology, 2017, 126(1): 173–190.
[16] Gätke MR, Viby-Mogensen J, Rosenstock C, et al. Postoperative muscle paralysis after rocuronium: less residual block when acceleromyography is used[J]. Acta Anaesthesiol Scand, 2002, 46(2): 207–213.
[17] Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit[J]. Anesthesiology, 2008, 109(3): 389–398.
[18] Murphy GS, Szokol JW, Marymont JH, et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit[J]. Anesth Analg, 2008, 107(1): 130–137.
[19] Srivastava A, Hunter JM. Reversal of neuromuscular block[J]. Br J Anaesth, 2009, 103(1): 115–129.
[20] Keating GM. Sugammadex: a review of neuromuscular blockade reversal[J]. Drugs, 2016, 76(10): 1041–1052.
[21] Jones RK, Caldwell JE, Brull SJ, et al. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine[J]. Anesthesiology, 2008, 109(5): 816–824.
[22] Della Rocca G, Pompei L, Pagan de Paganis C, at al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study[J]. Acta Anaesthesiol Scand, 2013, 57(9): 1138–1145.
[23] Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study[J]. Br J Anaesth, 2015, 115(5): 743–751.
[24] Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex[J]. Minerva Anestesiol, 2016, 82(7): 735–742.
[25] Ledowski T, Falke L, Johnston F, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal[J]. Eur J Anaesthesiol, 2014, 31(8): 423–429.
[26] Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man[J]. Br J Anaesth, 1980, 52(1): 69–76.
[27] Eikermann M, Zaremba S, Malhotra A, et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing[J]. Br J Anaesth, 2008, 101(3): 344–349.
[28] Herbstreit F, Zigrahn D, Ochterbeck C, et al. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure[J]. Anesthesiology, 2010, 113(6): 1280–1288.
[29] Rudolph MI, Chitilian HV, Ng PY, et al. Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications[J]. Anaesthesia, 2018, 73(9): 1067–1078.